![VBI Vaccines Announces Biomarker Data from VBI-1901 Phase 1/2a Study in Recurrent GBM Presented at ESMO Virtual Congress 2020 - VBI Vaccines VBI Vaccines Announces Biomarker Data from VBI-1901 Phase 1/2a Study in Recurrent GBM Presented at ESMO Virtual Congress 2020 - VBI Vaccines](https://www.vbivaccines.com/wp-content/uploads/2020/09/ESMO-2020-Poster.png)
VBI Vaccines Announces Biomarker Data from VBI-1901 Phase 1/2a Study in Recurrent GBM Presented at ESMO Virtual Congress 2020 - VBI Vaccines
![DBPi at ESMO Congress'22 representing Prostate Cancer patient survey | DontBePatient Intelligence GmbH DBPi at ESMO Congress'22 representing Prostate Cancer patient survey | DontBePatient Intelligence GmbH](https://www.dontbepatient.com/dbp-data/uploads/esmo22.jpg)
DBPi at ESMO Congress'22 representing Prostate Cancer patient survey | DontBePatient Intelligence GmbH
Imugene Limited - Our ESMO Asia 2019 poster presentation is now available for download http://ow.ly/NPEX50xhTvR | ASX: IMU #Oncology #BioTech #EndCancer #Immunotherapy #Cancer | Facebook
![ESMO14 - Poster: STRIDE, a randomised, phase 2, open-label study of sipuleucel-T with concurrent versus sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) ESMO14 - Poster: STRIDE, a randomised, phase 2, open-label study of sipuleucel-T with concurrent versus sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)](https://www.urotoday.com/images/stories/conferences/esmo/esmo_2014_P12-2-poster_final.jpg)